Clinical Trials Logo

Clinical Trial Summary

This study evaluates the addition of BIV201 (terlipressin diacetate) as a continuous infusion in addition to standard of care (diuretics and therapeutic paracentesis) for reduction of ascites and complications in adult patients with refractory ascites secondary to decompensated cirrhosis


Clinical Trial Description

Terlipressin has been shown to reduce portal hypertension, improve renal function and induce natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is approved in Europe for the treatment of bleeding esophageal varices and HRS type 1 and is usually administered as an IV bolus starting at 1 mg every 6 h and increased to 2 mg every 6 h (maximum 8 mg/day depending on response). This study will evaluate the use of terlipressin delivered by continuous infusion for two 28 day treatment cycles for reduction of ascites accumulation and complications in adult patients with refractory ascites secondary to decompensated cirrhosis. Continuous infusion allows for a significant reduction in the daily effective dose required for treatment and improved safety of terlipressin delivered as a low-dose continuous infusion could enable its use in the outpatient setting in the prolonged treatment of patients with refractory ascites. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04112199
Study type Interventional
Source BioVie Inc.
Contact
Status Terminated
Phase Phase 2
Start date June 17, 2021
Completion date May 8, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02891642 - Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
Recruiting NCT00239096 - Prevention of Decompensation in Liver Cirrhosis Phase 4
Active, not recruiting NCT03973866 - Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) N/A
Completed NCT01349348 - Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites Phase 3
Terminated NCT01455246 - Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Completed NCT01578226 - Procalcitonin in Cirrhotic Patients at High Risk for Sepsis N/A
Terminated NCT00548366 - Sodium Restriction in the Management of Cirrhotic Ascites Phase 4
Recruiting NCT05025878 - 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A
Not yet recruiting NCT04550091 - Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
Not yet recruiting NCT01716611 - Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Phase 4
Completed NCT01769040 - Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis Phase 4
Recruiting NCT05511766 - Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis Phase 2/Phase 3
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT05013502 - Empagliflozin in Diuretic Refractory Ascites Phase 1
Not yet recruiting NCT06436807 - PMCF Study of the CE-marked Drainova® ArgentiC Catheter
Completed NCT03263598 - Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
Completed NCT00907673 - The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure N/A
Terminated NCT00796861 - Trial of Sunitinib for Refractory Malignant Ascites Phase 2
Suspended NCT00511394 - Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis N/A